A股史上最貴新股——義翹神州(301047.SZ)首日上市高開104.8%
格隆匯8月16日丨義翹神州(301047.SZ)今日首日上市高開104.8%報599.9元,市值408億元。該股發行價格292.92元/股,超越石頭科技,刷新了A股史上的發行價最高紀錄公司是國內領先的生物試劑科技公司之一,從事生物試劑研發、生產、銷售並提供技術服務,主要業務包括重組蛋白、抗體、基因和培養基等產品,以及重組蛋白、抗體的開發和生物分析檢測等服務。公司在2019年中國重組蛋白試劑市場佔有率達到4.9%,位列第三,在國產廠商中位列第一。2018-2020年,義翹神州營收分別為1.39億元、1.81億元及15.96億元,歸屬於母公司股東淨利潤為3635.35萬元、3641.09萬元及112,760.75萬元;公司2020年營收爆發性增長7倍多,淨利潤增長幅度顯著高於營業收入增長幅度,而公司毛利率更是達到96.88%,同比上升11.49個百分點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.